8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T14692 | BMX-IN-1 | BMX kinase inhibitor | BTK |
BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine kinase (BTK, IC50 = 10.4 nM), but BMX-IN-1 is more than 47-656 ... | |||
T4268 | CHMFL-BMX-078 | BTK | |
CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM. | |||
T5524 | Aurora kinase inhibitor-3 | Aurora Kinase Inhibitor III | Aurora Kinase |
Aurora kinase inhibitor-3 (Aurora Kinase Inhibitor III) is a potent inhibitor of Aurora A kinase (IC50 = 42 nM).1 It is selective for Aurora A over BMX, BTK, IGF-1R, c-Src, TRKB, SYK, and EGFR. | |||
T12673L | PF-06250112 | BTK | |
PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC (IC50s: 0.9 nM and 1.2 nM, respectively). | |||
T73276 | BTK-IN-23 | ||
BTK-IN-23 is a BTK inhibitor with an IC50 value of 12.8 nM, demonstrating kinase selectivity superior to Ibrutinib [1]. It also effectively inhibits BLX and BMX, with IC50 values of 35.6 nM and 5.7 nM, respectively. | |||
T12673 | (Rac)-PF-06250112 | Others | |
(Rac)-PF-0625011 is a racemic form of PF-06250112, a potent and highly selective BTK inhibitor that is orally bioavailable. It also demonstrates an inhibitory effect on the BMX non-receptor tyrosine kinase and TEC [1]. | |||
T73275 | BTK-IN-22 | ||
BTK-IN-22, a BTK inhibitor (IC 50: 0.9 nM), also exhibits inhibition against BLX and BMX with IC 50 values of 1.4 and 1.2 nM, respectively. Demonstrating enhanced kinase selectivity, BTK-IN-22 outperforms Ibrutinib in th... | |||
T4413 | Poseltinib | ||
Poseltinib is an orally active, selective, and irreversible Bruton's tyrosine kinase (BTK) inhibitor, exhibiting a half-maximal inhibitory concentration (IC 50) of 1.95 nM. It demonstrates 0.3, 2.3, and 2.4-fold greater ... |